FDAsafety guidance72% confidence
FDA approves isatuximab-irfc for subcutaneous injection for multiple myeloma indications
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Sanofi.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Hematology · Multiple Myeloma
- Sub-indication
- General
Related signal: Isatuximab Evaluated in Stem Cell Transplant for Multiple Myeloma and Lymphoma